Rick Simpson Oil (RSO) in South Dakota: The Complete Guide by OilWell Cannabis

For South Dakotans navigating chronic pain, cancer treatment side effects, PTSD, or sleep disorders, the search for effective relief often leads to the same question we hear daily from patients in Sioux Falls, Rapid City, and rural communities across the state: “What is Rick Simpson Oil, and does it actually work?” We at OilWell Cannabis—based in Houston, Texas—have built our entire company around answering that question honestly, backed by the most rigorous scientific evidence available, and making our formulations accessible to South Dakota residents without requiring a medical card or long drives to limited dispensary locations.

South Dakota’s unique healthcare landscape makes RSO education particularly critical. With vast rural areas where specialist care can be hours away, an aging population facing chronic conditions, and a veteran community that deserves better options than endless prescription cycles, our state needs transparent cannabis education more than most. This guide exists because South Dakotans deserve to understand exactly what they’re putting in their bodies, what the science actually says, and how to access legal, lab-tested products safely.

Understanding Rick Simpson Oil: The History South Dakota Needs to Know

Who Rick Simpson Was (And Why His Story Matters Here)

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada—not a doctor, not a scientist, but a power engineer and maintenance worker whose path mirrors what many South Dakotans have experienced: a regular person failed by conventional medicine who found answers in cannabis. That matters for South Dakota because our state has one of the highest rates of workplace injuries in agriculture, construction, and energy sectors. When Simpson fell from scaffolding in 1997 at a hospital in Moncton, New Brunswick, suffering a serious head injury with persistent tinnitus and post-concussion symptoms, the medications doctors prescribed either didn’t help or made him worse. Sound familiar? We’ve heard the same story from farmers outside Pierre and mechanics in Aberdeen—doctors hand out pills that don’t work, and when you ask about cannabis, you’re dismissed.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study at the Medical College of Virginia where NIH-funded researchers reported THC slowed or shrunk tumors in mice. That study—intended to demonstrate harm, not benefit—became Simpson’s foundational reference, even though its findings were never replicated in controlled human cancer trials. This is the kind of historical context South Dakota readers need: understanding that early cannabis research sparked hope, but also recognizing the gap between mouse studies and human outcomes.

The pivotal moment came in 2003 when Simpson reported three bumps on his arm diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. Important context: No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in any peer-reviewed source. This is personal testimony, not medical evidence. But it’s historically significant as the catalyst for a global movement—and it’s why so many South Dakota cancer patients first hear about RSO through online forums rather than their oncologists.

The Crusade: How RSO Went From One Man to a Global Movement (And Eventually to South Dakota)

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil, giving it away for free to cancer patients and others in his community in Maccan, Nova Scotia. He helped people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more. For South Dakotans living in counties without pain specialists or mental health services, this free-distribution model resonates deeply. We’ve all known someone who drove two hours to a specialist only to receive another prescription that didn’t work.

Simpson’s story reached the world through the 2005 documentary Run From The Cure, which became foundational in cannabis communities. For many South Dakotans who discovered RSO through YouTube or Facebook patient groups, this film was their introduction to concentrated cannabis oil as medicine. It was distributed freely online and framed Simpson’s work as a grassroots challenge to pharmaceutical interests.

But Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009, charging him with cultivation, possession, and trafficking. He was eventually convicted and left Canada for Europe, living in Croatia and the Netherlands while continuing his advocacy. This legal conflict context matters for South Dakota because our state has its own complex cannabis history. While medical cannabis became legal in 2020, the regulatory framework remains restrictive. Many South Dakotans still remember when cannabis possession meant serious legal consequences, and Simpson’s story of being punished for helping sick people resonates with that experience.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his information platform. Throughout his career, he maintained that cannabis oil could cure cancer and that pharmaceutical companies and government agencies were suppressing this knowledge. Important context: This conspiratorial framing reflects a worldview shared by many in the early cannabis movement. We present it to understand RSO’s cultural significance, not to endorse it. South Dakota readers deserve honesty about both Simpson’s passion and the evidence gaps in his claims.

The Traditional RSO Protocol: What South Dakota Patients Need to Know

Simpson’s core recommendation was a 60-gram oral protocol over roughly 90 days. For South Dakota cancer patients urgently searching online for dosing guidance, this protocol often appears as the only option. We’re providing the full details here because you deserve complete information, followed by critical evaluation.

The 60-Gram Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum for serious cancer treatment.

The Titration Schedule

• Week 1: Start with half a grain of dry rice-sized dose (10-15mg) taken three times daily. Total daily intake: 30-45mg.
• Weeks 2-5: Double the dose every four days, building tolerance gradually. Target: 1 gram (1,000mg) per day by week 5-6, divided into three doses.
• Weeks 5-12: Maintain 1 gram per day (333mg per dose) until all 60 grams are consumed.

Administration Methods

• Oral: Primary method—place under tongue or swallow for systemic absorption.
• Topical: For skin cancers, apply directly to lesions with bandages, changing every 3-4 days.
• Inhalation: Not recommended as primary treatment, though acknowledged for immediate symptom relief.

Tolerance and Psychoactive Effects

Simpson claimed patients develop THC tolerance within 3-4 weeks, with psychoactive effects being temporary. He recommended nighttime dosing initially and warned against driving. For South Dakota residents who work long hours, commute long distances, or operate equipment on farms and ranches, these impairment warnings are critical.

Important Context for Evaluating This Protocol

This is where South Dakota readers need to pause and understand the evidence:

• No controlled trial validation. Zero published randomized controlled trials, cohort studies, or even well-documented case series support this specific 60-gram/90-day protocol for any cancer type or condition.
• Crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied wildly depending on starting plant material and extraction technique.
• Extremely high THC exposure. At peak dosing (1 gram per day of 60-90% THC oil), patients consumed 600-900mg of delta-9 THC daily. For perspective, FDA-approved synthetic THC (dronabinol) is typically dosed at 2.5-20mg per day.
• Real risks at these doses. Consuming 600-900mg of THC daily carries serious risks: severe intoxication, anxiety, panic, tachycardia, hypotension, cannabis use disorder, and impairment that makes operating South Dakota’s farm equipment or navigating icy rural roads extremely dangerous.
• Oncology complexity. Cancer patients are medically vulnerable. Using unregulated, unstandardized cannabis oil as primary treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

What Traditional RSO Actually Was

Understanding the original product helps South Dakota readers evaluate what’s being sold locally.

Source Material: Single high-THC indica strains, no standardization. If you’re buying “RSO” from a South Dakota dispensary, unless they publish their strain source, you’re getting unknown starting material.

Extraction Solvent: Simpson used naphtha (petroleum-based) or 99% isopropyl alcohol—neither food-grade. Naphtha may contain benzene, toluene, and other carcinogens.

Extraction Process: Bucket, solvent, agitation, cheesecloth filtration, rice cooker evaporation. Simple but risky—especially the fire hazard of evaporating flammable solvents, a real concern for South Dakota residents in rural homes.

Appearance: Nearly black, thick, tar-like oil with strong cannabis and possible solvent-residual smell.

Cannabinoid Profile: Fully decarboxylated, THC-dominant (60-90% estimated), minor cannabinoids at natural ratios—uncontrolled, unmeasured, never lab-verified.

Terpene Content: Minimal to none. The solvent and high-heat process destroyed terpenes.

Standardization: None. Every batch was different. No Certificates of Analysis (COAs), no contaminant screening.

Residual Solvent Risk: This is critical. Incomplete solvent purging leaves potentially harmful residues. Modern extraction uses food-grade ethanol or CO₂ with validated testing—exactly what OilWell uses.

Simpson’s Claims vs. The Evidence: What South Dakota Patients Deserve to Know

Rick Simpson claimed RSO could cure cancer and treat diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and more. Let’s evaluate these against actual evidence:

What Simpson Was NOT

He had no formal medical, oncology, pharmacology, or clinical research training. He never conducted or published a trial. His evidence was personal experience and testimonials—no controls, no verification, no imaging confirmation, no long-term follow-up.

What Preclinical Literature Shows

Lab and animal studies show THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal models show some tumor-growth inhibition. This research is scientifically interesting and ongoing.

What Preclinical Literature Does NOT Show

These findings have NOT translated into proven human cancer cures. The gap between animal results and human outcomes is vast. No human clinical trial has demonstrated RSO cures cancer. Small exploratory trials in glioblastoma have been conducted but haven’t produced cure-level results.

Institutional Positions

• National Cancer Institute (NCI): Acknowledges laboratory and animal model studies but does NOT endorse cannabis as cancer treatment.
• FDA: Has NOT approved any cannabis plant product for cancer. Only Epidiolex (CBD for seizures) and synthetic THC analogues for chemo nausea/AIDS wasting are approved.
• Health Canada: Never approved RSO for cancer.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer cure.

What Simpson Got Right

He drew attention to cannabinoids as serious biomedical research when the world ignored them. His advocacy helped create conditions for today’s legal cannabis industry and research infrastructure. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated

His cancer cure claims exceeded the evidence. Encouraging patients—especially cancer patients—to rely on RSO instead of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm. Delayed or foregone treatment is a documented concern in alternative medicine. For South Dakota residents facing long drives to cancer centers in Sioux Falls or Rapid City, the temptation to delay treatment in favor of an “easier” option is real—and dangerous.

The Legacy: Why “RSO” Now Means Many Things

Today, “RSO” is used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to Simpson’s original oil. In South Dakota dispensaries, RSO can mean almost any full-spectrum extract in a syringe, regardless of extraction method, cannabinoid profile, or quality.

Simpson himself has criticized commercial products that use the RSO name while departing from his method and philosophy. He gave oil away for free; commercialization contradicts his original intent. Whether this evolution represents improvement (quality control, testing) or betrayal (profit, gatekeeping) depends on perspective. The cannabis community remains divided.

What is not disputed: modern RSO has evolved substantially, and those changes matter for South Dakota consumers who need to understand what they’re actually buying.

Traditional RSO vs. Modern Formulated RSO: A Comparison South Dakota Needs

Dimension	Traditional RSO	OilWell Formulated RSO
Source Material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction Method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid Profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene Content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab Testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual Solvents	Significant risk with naphtha	Controlled and tested—solvent-free production
Dosing Precision	Approximate, syringe-based	Measured per mL with graduated dropper
Product Formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa Preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Delta-9 THC Dominance	60-90% delta-9 THC	Only 90 mg delta-9 THC total in 30 mL bottle (plus 1,500 mg convertible THCa)

Why OilWell’s Formulas Diverge From Traditional RSO

Our formulations are deliberately different, solving problems that limited Simpson’s original vision:

Multi-Cannabinoid Approach: Traditional RSO relied on whatever single strain was available. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation: Traditional RSO had essentially no terpene content. We include live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at the preclinical level [20][21][23][24][25][26][27][28][29].

THCa as Separate Ingredient: Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity lost during conversion [12].

Reduced Delta-9 THC Dominance: Traditional RSO was overwhelmingly delta-9 THC. Our formula uses only 90 mg delta-9 THC while distributing cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), CBN (750 mg), and CBC (750 mg)—reflecting broader cannabinoid research rather than single-compound dominance.

Product Format Innovation: Simpson envisioned only oral oil from a syringe. We offer both 30 mL sublingual oil and 1-gram vape cartridge, each with format-specific formulation acknowledging different pharmacokinetic profiles [14].

Solvent Safety: Why South Dakota Should Care

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves harmful residues.

Modern extraction uses food-grade ethanol or supercritical carbon dioxide (CO₂) with validated testing. This is one of the most straightforward improvements the regulated cannabis industry made over traditional RSO. For South Dakota residents considering DIY extraction (common in areas without dispensaries), understanding solvent risk is critical. Our solvent-free production eliminates this concern entirely.

The Decarboxylation Choice: Patient Control Matters in South Dakota

Traditional RSO was always fully decarboxylated—heat converted all THCa to delta-9 THC, leaving patients no choice about psychoactivity. This is a major limitation for South Dakota’s working population.

Our sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, No Heat: All 1,500 mg stays as THCa, completely non-psychoactive. Provides anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Compatible with daytime work, driving, farm equipment operation—zero impairment.

Option 2—Fully Activated, Home Decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. Converts 1,500 mg THCa into approximately 1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC—achieving psychoactive potency comparable to traditional illegal RSO, 100% legally. Transfer a controlled portion to a second container to decarb only what you need, preserving the rest as THCa.

Option 3—Vape, Auto-Decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Fastest-onset RSO delivery method—1-2 minutes.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC, reflecting CO₂ loss during decarboxylation.

For South Dakota residents who need to function during the day but want full therapeutic strength at night, this patient-controlled potency is revolutionary. You decide—not the product.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with low boiling points (21-157°C). Traditional RSO’s solvent extraction and high-heat evaporation destroyed them completely. The finished oil was cannabinoid-only, despite coming from a terpene-rich plant.

Our formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each has its own evidence profile discussed below. The entourage-effect literature [20][29] provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically.

Evidence Standards: Then and Now

Rick Simpson operated pre-legalization, pre-testing, pre-research. When he began in the early 2000s, cannabis was illegal in Canada and most of the world. No regulatory framework, no standardized testing, no legal pathway for clinical research, no peer-reviewed cannabis journals. Personal experience was the only evidence currency.

We operate with full access to peer-reviewed literature and institutional sources. This document applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews, institutional summaries, then preclinical literature [1]-[29]. Every compound claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

Where Simpson relied on personal testimony, we rely on published literature. That’s the standard South Dakota patients deserve.

About OilWell Cannabis: Our Story, Your Access

From McAllen to Houston to South Dakota

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Mexico, in the Borderplex region. This is one of the most economically challenged and dangerous areas along the border. McAllen has vibrant culture but limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by cartel violence. Colin’s childhood was shaped by this harsh reality.

By age sixteen, Colin had to leave home. He learned to hustle, taking on risky border transport work. Many of his best friends have been killed or imprisoned. He’s faced every form of violence imaginable. But instead of falling into harder substances, he focused on cannabis—seeing it as safer and more beneficial. He grew up in the traditional cannabis world pre-legalization, learning the plant intimately while operating in the shadows, then transitioned to legal business.

Later, Colin became a formally trained software engineer and did custom development for Baylor College of Medicine—one of the most prestigious medical institutions in the Texas Medical Center. That combination of deep cannabis plant knowledge plus medical-grade technical precision defines OilWell’s approach and directly benefits South Dakota patients who expect pharmaceutical-level precision.

Bentley’s Story: Where Our Mission Began

OilWell’s origin isn’t in a boardroom—it starts with a dog named Bentley. Bentley was family, Colin’s companion through the toughest times. When Bentley fell seriously ill, veterinarians recommended euthanasia. He was paralyzed in his back legs. Pain medications would destroy his organs. The choice seemed to be prolonged suffering or mercy killing.

But Colin had faced too much loss. Bentley was a fighter. In desperation, Colin discovered CBD—through a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” from rescue worker Jessica.

Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It wasn’t a cure, but it was hope. And that hope delivered what veterinary medicine said was impossible: Bentley got up, walked over, and brought Colin his ball. From paralyzed to playing. This wasn’t placebo—dogs don’t respond to placebo. This was cannabinoid medicine succeeding where pharmaceuticals failed.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized formulas for every condition Bentley faced:

• Neurodegeneration → CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure
• Arthritis → Multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork. This is why our RSO contains seven cannabinoids, not one or two.

This journey became Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering—not just for pets, but for people. Bentley’s story is OilWell’s foundation, driving our commitment to quality, innovation, and compassionate care.

Colin’s Personal Battle: PTSD, Benzo Addiction, and Peace Gummies

Colin knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to quit Xanax, he did it cold turkey—a notoriously difficult and dangerous feat—using the cannabinoid knowledge he developed keeping Bentley alive.

Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This is not theoretical knowledge. He lived what RSO patients live: desperation for relief, failed pharmaceuticals, discovering that cannabinoids work when pills do not.

Our formulas are now used by doctors for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. We’ve developed formulations for vegans, diabetics, and those with specific dietary needs.

ABC13 Houston: Seven Features Over Four Years

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving America’s fourth-largest city—featured Colin and OilWell in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

Why does this matter for South Dakota? Mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When you’re deciding whether to trust a cannabis company from Texas to ship to South Dakota, knowing that Houston’s top news source repeatedly identified Colin as the primary cannabis industry expert provides assurance that no marketing campaign could replicate.

Our foundational quote from September 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This philosophy guides everything. We don’t overpromise. We provide the best possible version of information so you can decide.

Current Operations: Real Business, Real Reach

OilWell operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). Since 2019, we’ve generated approximately $1M annual revenue, maintain a near-5.0 Google rating, and hold a Texas DSHS license. All artwork, formulations, and packaging are created in-house in Houston—not mass-produced, but carefully crafted with personal touch.

For South Dakota customers, our location means:

• Same-day delivery isn’t available (we’re 1,000+ miles away), but we offer fast nationwide shipping via USPS Priority Mail (2-3 business days) or FedEx/UPS Ground (3-5 days)
• Discreet packaging with no cannabis branding visible—important for South Dakota’s conservative communities
• Temperature-stable packaging for South Dakota’s extreme seasonal temperature swings
• Full documentation including Certificates of Analysis for every shipment

The OilWell RSO Philosophy: Four Principles That Matter for South Dakota

Our RSO is NOT traditional RSO. It’s a formulated, multi-cannabinoid product informed by tradition but departing from it in deliberate, evidence-motivated ways:

1. Accessibility Over Gatekeeping
No medical card required. Anyone age 21+ can purchase. We ship nationwide to South Dakota and internationally where hemp products are legal. Simpson believed medicine should be accessible to everyone; we’ve built a product and distribution model that makes that legally possible for South Dakotans without requiring trips to limited dispensaries in Sioux Falls or Rapid City.

2. Patient-Controlled Potency
THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for daytime relief without impairment or decarboxylate it for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-Source Formulas
We publish our complete formulas publicly—every cannabinoid, every milligram, every percentage—so if you can’t afford our products, you can source ingredients and make your own. Simpson gave oil away free; we adapted that ethos for the modern marketplace by selling professionally manufactured products AND publishing the recipe.

4. Evidence-Informed, Not Evidence-Overstating
The GENERAL KNOWLEDGE section you’re reading represents our commitment to honest education. Simpson operated without peer-reviewed literature; we have that access and use it to distinguish what’s well-supported, what’s emerging, and what’s overstated. South Dakota patients deserve that honesty.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC by dry weight. Our RSO Sublingual Oil contains only 90 mg delta-9 THC in the entire 30 mL bottle (3 mg/mL)—well under the threshold. All cannabinoids are hemp-derived, making our product federally legal and legal in most states.

For South Dakota specifically: South Dakota adopted the Farm Bill’s hemp provisions, making hemp-derived cannabinoid products legal statewide. However, local law enforcement and prosecutors may have varying interpretations. We provide full documentation with every shipment, but South Dakota customers accept responsibility for understanding and complying with local laws.

THCa’s legal significance: It’s the acidic, non-psychoactive precursor to delta-9 THC. At point of sale, THCa is Farm Bill compliant because it hasn’t been converted to delta-9 THC. When you heat it at home to 260°F (125°C) for 45-60 minutes, 1,500 mg THCa converts to approximately 1,315 mg delta-9 THC. Combined with the existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC—giving you psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after legal purchase.

Important legal notice for South Dakota customers: THCa converts to delta-9 THC when heated. You are responsible for understanding South Dakota laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International and out-of-state customers accept all customs and legal responsibility.

Open-Source Formulas: Why We Publish Everything

We publish complete formulas so anyone who can’t afford our products can make their own. This is a direct echo of Rick Simpson’s free-distribution ethos. For South Dakota residents on fixed incomes, in rural areas with limited employment options, or facing medical expenses that strain budgets, this matters.

The Bentley Golden Paste Recipe (Our Original Open-Source Formula)

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (critical for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes)
2. Add coconut oil and black pepper, stir until thoroughly mixed
3. Cool and store in refrigerator up to two weeks
4. Add CBD oil before serving, adjusting dosage based on pet’s weight and needs

Serving: Mix small amount with pet’s food once or twice daily. Monitor changes and consult veterinarian. This recipe is free, useful, and demonstrates our character better than any marketing copy.

The Decarboxylation Choice: Empowering South Dakota Patients

Our sublingual formula contains 1,500 mg THCa, creating three distinct usage options:

Option 1—Raw, No Heat: Completely non-psychoactive. THCa provides anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Compatible with work, driving, operating farm equipment—zero impairment.

Option 2—Fully Activated, Home Decarboxylation: Heat at 260°F for 45-60 minutes. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC—psychoactive potency comparable to traditional illegal RSO, 100% legally because you control the activation.

Option 3—Vape, Auto-Decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Fastest-onset RSO delivery available.

Conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation (CO₂ loss). You control the potency—the ultimate patient empowerment.

Solvent-Free Production: Safety First

We don’t use extraction solvents. Our RSO is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha, no isopropyl alcohol, no butane. This eliminates the residual solvent risk that is one of traditional RSO’s most significant safety concerns.

We use organic MCT oil as the carrier base—a food-grade lipid that facilitates sublingual absorption and provides neutral taste. This is a major improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-party lab testing covers cannabinoid potency, terpene profile, pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis are available on request and through our website.

Our Broader Product Portfolio

Beyond RSO, we offer:

Asshole Peach — Our most popular product, carefully formulated for euphoric, long-lasting sensation. Particularly favored by veterans for pain and PTSD relief without excessive aggression. South Dakota’s significant veteran community may find this especially relevant.

Peace Gummies — Developed from Colin’s personal PTSD and benzo withdrawal experience. Helped him quit Xanax cold turkey. Also available in vape form for quick relief—Colin personally uses it for insomnia and severe PTSD.

Custom Creations — We design targeted products on request for specific cannabinoid ratios, delivery formats, or unique health circumstances, including formulations for vegans, diabetics, and those with specific dietary needs.

Two Product Formats: Choose What Fits Your South Dakota Lifestyle

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL dosing
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximately 40-60 doses per bottle

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual (no separate delta-9 THC listed—auto-decarbs when vaped)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to Use Each Format: South Dakota Use Cases

Use Case	Recommended Format	Rationale	South Dakota Example
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset	Breakthrough pain during fieldwork
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration	Managing arthritis through long winter days
Maximum bioavailability	Sublingual	13-19% absorption	Getting most from each dose on fixed income
Portability/discretion	Vape	Compact, no measuring	Discreet use during community events
Precise dosing control	Sublingual	Graduated dropper	Fine-tuning for specific conditions
Daytime non-psychoactive	Sublingual (raw)	Zero impairment	Operating equipment, driving to town
Nighttime psychoactive	Sublingual (decarbed) or Vape	Activated THCa + delta-8	Sleep support after stressful day

Competitive Comparison: Why OilWell Stands Out for South Dakota

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP Dispensary	OilWell
Cannabinoids	THC-only (420 mg per 0.5 g)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG Content	0 mg	3,000 mg
CBN Content	0 mg	750 mg
CBC Content	0 mg	750 mg
Potency Control	No—always psychoactive	Yes—THCa non-psychoactive until you heat it
Access Requirements	TCUP medical card + qualifying condition	Age 21+ only, no medical card needed
Qualifying Conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary	Ships directly to South Dakota
Farm Bill Compliant	No—state medical program	Yes—<0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total Cannabinoids	1,000 mg	16,590 mg
CBD Content	~950 mg	4,500 mg
CBG Content	15.5 mg	3,000 mg
CBN Content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive Option	No meaningful effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate Price	$40-50	$129.99

Condition-Specific Usage Context for South Dakota Residents

Important Disclaimer: These contexts are informed by cannabinoid research cited below and our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatments, and NOT substitutes for professional medical care. These products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent disease. Always consult a qualified healthcare provider before use, especially if you have medical conditions, take medications, are pregnant/nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0 mL sublingual ~1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence: delta-8 THC antiemetic [9], delta-9 THC nausea evidence [1][13], CBD anxiolytic buffering [3]

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual—anti-inflammatory without impairment
• Nighttime: 0.5-1.0 mL decarbed sublingual—pain relief + CBN sleep support
• Breakthrough pain: Vape as needed
• Evidence: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

Sleep Support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN—the dosage investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN—above threshold for reduced sleep disturbance
• Evidence: CBN sleep evidence [16][17], cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full profile including CBN for sleep architecture
• Evidence: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage effect [20]

General Titration Principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary by body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery to South Dakota: How You Get Our Products

We ship nationwide to all 50 states where Farm Bill-compliant products are legal, including South Dakota.

Shipping Options:

• USPS Priority Mail: 2-3 business days to most South Dakota addresses (Sioux Falls, Rapid City, Aberdeen, Brookings, Watertown, Mitchell, Yankton, Pierre, Huron, Vermillion, and rural routes)
• FedEx/UPS Ground: 3-5 business days
• Discreet packaging with no cannabis branding visible—respecting South Dakota’s conservative community values
• Temperature-stable packaging for South Dakota’s extreme seasonal temperature swings (-30°F winters to 100°F summers)
• Full documentation including Certificates of Analysis for every order
• Signature-required option available for added security

We cannot offer same-day delivery to South Dakota (our Houston operation is ~1,000 miles away), but we process orders within 24 hours and provide tracking so you know exactly when your package arrives.

For South Dakota’s veteran community: We ship to VA facilities, veteran homes, and rural addresses statewide. The COVID vaccine giveaway we coordinated in Houston demonstrated our community commitment—we bring that same dedication to serving South Dakota veterans.

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile documented in the GENERAL KNOWLEDGE section above. We apply the same evidence hierarchy to our own products that we apply to the broader cannabinoid field.

Where we make specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework. We don’t exempt ourselves from these standards. That’s how South Dakota patients can trust that our claims are grounded in actual science, not marketing hype.

General Knowledge: The Science Behind Every Ingredient

Research Method and Evidence Weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic/preclinical literature when human data are sparse. This matters because the evidence base is uneven—CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes rely more on reviews, animal work, and preclinical pharmacology [1]-[29].

South Dakota residents deserve to understand this hierarchy. When a local dispensary claims “CBN is great for sleep,” you should know the actual human evidence is weak [16][17]. When someone says “myrcene causes couch-lock,” you should know human proof is limited [20][23]. This is the education that protects you from overspending on products that can’t deliver what they promise.

Institutional Baseline from NIH and Related Sources

• NCCISH states the strongest established cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and HIV/AIDS appetite/weight loss. Modest evidence exists for chronic pain and MS symptoms. Many claimed uses remain early-stage research [1].
• FDA has not approved the cannabis plant itself for medical use. Only purified CBD (Epidiolex for seizures) and synthetic THC analogues (for chemo nausea/AIDS wasting) have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, and THC-vape lung injury [1].
• NCCIH warns over-the-counter CBD products may differ from labels and CBD itself has been associated with decreased alertness, GI effects, liver abnormalities, and drug interactions [1].

Cannabinoid Profiles

CBD (Cannabidiol)

• Evidence profile: Strongest human evidence in our formula, especially as purified product [1]-[6]
• Best supported: Seizure disorders (FDA-approved Epidiolex) [1][2]
• Anxiety: 2024 systematic review of 316 participants across 8 studies showed significant anxiolytic signal, but authors stress limited clinical sample and need for more trials [3]
• Pain: 2024 systematic review found promising but heterogeneous literature, with trial quality limiting broad analgesic claims [4]
• Sleep: 2023 insomnia review found methodologically weak literature, few objective assessments [5]
• Safety: 2023 systematic review found liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy [6]. NCCIH flags diarrhea, sleepiness, appetite changes, mood effects, liver abnormalities, drug interactions [1].
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications rather than broad wellness claims [1]-[6]

CBG (Cannabigerol)

• Evidence profile: Mostly review-level and preclinical; sparse human evidence [7][8]
• Pharmacology: CBG is biosynthetic precursor to major cannabinoids; interacts with cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling—mechanistically interesting but not clinically established [7]
• Research areas: Possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity—primarily pharmacology-led hypotheses/preclinical findings [7][8]
• Caution: 2021 pharmacology review notes CBG is sold commercially while evidence base remains thin—claims outrun science [7]
• Bottom line: Serious research topic but should be described as promising minor cannabinoid with limited clinical validation, not proven therapeutic [7][8]

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar pharmacokinetic/pharmacodynamic behavior. Delta-8 is partial CB1 agonist with cannabimimetic activity, appears less potent than delta-9, likely due to weaker CB1 affinity [9]
• Public health literature: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, public health concerns rather than strong human trials. Noted reports of adverse consequences, emphasized regulatory/product-quality concerns [10]
• Manufacturing context: Chemistry/pharmacology review notes commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels—product-byproduct and lab-testing questions matter [11]
• Bottom line: Should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, more manufacturing-quality uncertainty than many realize [9]-[11]

THCa (Tetrahydrocannabinolic Acid)

• Evidence profile: Important chemically/formulation-wise, low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC; may represent large share of THC-related content in raw plant material. Key issue: THCa decarboxylates to THC during heating and can change during storage/processing [12]
• Psychoactivity: THCa itself does not produce THC’s psychoactive effects, but distinction only holds if molecule stays acidic and isn’t substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—not equivalent to established human outcomes [12]
• Bottom line: Best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, storage. Any claim must account for possible conversion to THC [12]

Delta-9 THC

• Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, clearest adverse-effect burden [1][13]-[15]
• Institutionally best supported: NCCIH identifies THC-containing medicines relevant to chemo nausea/vomiting, HIV/AIDS appetite/weight loss, some MS/pain outcomes, while stressing many other uses remain uncertain [1]
• Pain evidence: 2022 systematic review found high-THC or comparable THC:CBD products may provide short-term pain benefit but increased dizziness, sedation, nausea, treatment discontinuation [13]
• Pharmacokinetics: Inhaled THC: onset seconds-minutes, peak 15-30 minutes, duration few hours. Oral THC: later onset, later peak, longer duration—matters for benefit and overconsumption risk [14]
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, concerning signals for anxiety/depression in nontherapeutic settings [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency potential, withdrawal, pregnancy concerns, accidental pediatric exposure, vape lung injury concerns [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15]

CBN (Cannabinol)

• Evidence profile: Weak human evidence; marketing moved ahead of data [12][16][17]
• What it’s marketed for: Sleep and sedation. Reputation widespread, clinical support far thinner than market suggests [16][17]
• Best sleep claim review: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated cannabis and sleep review concluded overall cannabinoid sleep research doesn’t match real-world use scale, need for better-designed, adequately powered trials substantial [17]
• Chemical context: THCa review notes THC can degrade toward CBN under certain conditions—explains why CBN discussed in aging/oxidized cannabis contexts [12]
• Bottom line: Clearest example where cultural reputation stronger than current clinical evidence base [16][17]

CBC (Cannabichromene)

• Evidence profile: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19]
• Pharmacology/interest: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids; highlights antinociceptive, antibacterial, anti-seizure as especially interesting research targets [18]
• Older literature: Review literature summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance—not yet strong evidence for patient-facing claims [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19]

Terpene Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human cannabis studies. 2024 entourage-effect review: terpene bioactivity plausible, sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence profile: Largely review and preclinical, useful safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities—overwhelming share from nonhuman/non-cannabis literature [21]
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22]
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22]

Myrcene

• Evidence profile: Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, discusses possible mechanisms, explicitly states human studies lacking [23]
• Interpretation caution: Myrcene often invoked in consumer language as proven sedating terpene explaining couch-lock or sleep effects. Stronger claim than human evidence currently supports [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23]

Caryophyllene

• Evidence profile: Among most mechanistically interesting due to direct cannabinoid-system relevance, but still mostly preclinical [24]
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual, makes it especially relevant when discussing cannabis terpenes pharmacologically rather than purely aromatic terms [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective repeatedly discussed in review literature, but human clinical confirmation remains limited [24]
• Bottom line: Arguably strongest candidate terpene with cannabinoid-system significance, but should not be described as clinically proven for outcomes commonly attributed to it [24]

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 pinene and linalool review found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, emphasized evidence mostly preclinical and well-designed clinical trials lacking [25]
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while emphasizing lack of robust human trials [25]
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26]
• Safety note: As with limonene, oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22]
• Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Evidence profile: Translationally interesting, but still early [20][27]
• Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, mood outcomes [27]
• Bottom line: One of more interesting terpene research targets, but remains far from clinically settled [27]

Terpinolene

• Evidence profile: One of least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 terpinolene review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research Limits and Interpretation: What South Dakota Should Know

1. Evidence base is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29].
2. Data categories aren’t interchangeable. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not the same. Common error: letting evidence from one category stand for another.
3. Minor cannabinoids/terpenes are commercially interesting BECAUSE underexplored. This also means claims often become inflated.
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent pharmacokinetics all materially affect real-world interpretation [1][10][11][14].
5. THCa chemistry changes with storage/heating. Storage and heating convert acidic cannabinoids to neutral cannabinoids like THC [12].

Common Overstatements to Avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, no strong validated-trial base yet identified [16][17].

Overstatement: Myrcene is proven human sedative that reliably causes couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].

Overstatement: Terpenes generally have proven entourage effects in patients.
More accurate: Entourage hypotheses influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa to THC, changing effective exposure [12].

Overstatement: Delta-8 THC is safe because hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for South Dakota Customers

• CBD and delta-9 THC have most evidence development
• Delta-8 THC is not trivial or purely mild—it’s psychoactive with less robust safety/efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing—don’t interpret raw, gently-handled, and heated formats the same way
• CBG, CBN, CBC are scientifically credible but clinically immature compared to CBD and THC
• Terpene claims should be careful—compound-specific human therapeutic claims only where directly supported

RSO Sublingual Oil Formula: The Complete Recipe

Cannabinoid	Amount (mg)
CBD	4,500
CBG	3,000
Delta-8 THC	6,000
THCa	1,500
Delta-9 THC	90
CBN	750
CBC	750
Total Cannabinoids	16,590

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper in 0.1 mL increments (55.3 mg cannabinoids per 0.1 mL)
• Price: $129.99

For South Dakota DIY makers: This is your recipe. Source individual cannabinoid distillates and isolates, mix at these exact ratios in organic MCT oil with 5% live terpenes. Use a calibrated scale and sterile equipment. We publish this because Simpson gave his oil away free—we honor that ethos by giving you the formula.

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1-gram cartridge
• 510-thread universal battery compatibility
• Note: No separate delta-9 THC listed—THCa auto-decarboxylates at vaping temperature (400-450°F)
• Price: $49.99

For South Dakota vapers: This formula delivers fastest onset (1-2 minutes) for acute symptom management. Compatible with standard vape batteries available at South Dakota vape shops and online retailers.

Terpene Profile (Both Products)

• Limonene (citrus-bright): Citrus notes, potential mood elevation
• Myrcene: Earthy, herbal foundation
• Caryophyllene (β-caryophyllene – pepper/spice): CB2 agonist, potential anti-inflammatory benefits
• Pinene (forest-fresh): Fresh pine aroma, potential clarity enhancement
• Linalool (floral, lavender): Calming floral notes
• Humulene (earthy, woody): Woody undertones, potential anti-inflammatory properties
• Terpinolene (piney, fruity, sparkling): Complex fruity-pine finish

For South Dakota residents familiar with our state’s pine forests (Black Hills, Custer State Park), the pinene terpene creates a sensory connection to home. The peppery spice of caryophyllene echoes locally grown crops. These aren’t just chemical names—they’re sensory experiences that make our product feel familiar.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know

2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.

3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.

4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.

5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.

6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.

7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.

8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.

9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.

10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.

11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.

12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.

13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.

14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.

15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.

16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.

17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.

18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.

19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.

20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.

21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.

22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.

23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.

24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.

25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34544304.

26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.

27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.

28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.

29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

For South Dakota Residents: Your Next Steps

If you’re in South Dakota and considering RSO, here’s what to do:

1. Read this entire guide. Understand the history, the science, and what makes our formula different.
2. Consult your healthcare provider. Especially important if you have medical conditions, take medications, are pregnant/nursing, or have health concerns. This is not optional—it’s essential.
3. Decide if you want to purchase or DIY. Our open-source formulas give you both options. If budget is tight, source the ingredients and make it yourself. If you want lab-tested precision, order from us.
4. Choose your format. Need fast relief for acute symptoms? Vape. Need sustained relief through the day? Sublingual. Need to work without impairment? Use raw sublingual. Need full potency at night? Decarb it.
5. Order or create. We ship discreetly to all South Dakota addresses with full documentation. Or gather ingredients and create your own using our exact specifications.
6. Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Every South Dakota resident’s response varies based on body weight, metabolism, tolerance, medications, and other factors.
7. Monitor and adjust. Keep a journal. Track symptoms, doses, effects. This data helps you optimize your regimen.

Legal Considerations for South Dakota

South Dakota legalized medical cannabis in 2020 but maintains a restrictive program. Hemp-derived products under 0.3% delta-9 THC are legal under state and federal law. Our products comply with these standards.

However, South Dakota law enforcement may have varying interpretations, particularly in rural counties. We provide:

• Full Certificates of Analysis with every shipment
• Detailed product descriptions and receipts
• Discreet packaging without cannabis branding
• Customer support to answer any questions

You accept responsibility for understanding and complying with South Dakota laws. We ship legally compliant products; how you use them is your responsibility.

Why South Dakota Can Trust OilWell

• Transparency: We publish our complete formulas—no secrets.
• Evidence: Every claim is tied to peer-reviewed research.
• Experience: Colin’s personal journey from PTSD and benzo addiction, Bentley’s decade of formulation development, and seven ABC13 features establish credibility.
• Quality: Lab-tested, solvent-free, organic MCT oil base, full COAs.
• Access: Ships directly to South Dakota, no medical card needed.
• Community: $35,000 COVID vaccine giveaway demonstrated our commitment to public health—not just profit.
• Ethics: Proactively removed Delta-8 products when legal status changed, warned other operators to protect consumers.

Order Today: Serving South Dakota with Integrity

Ready to try OilWell RSO? Here’s how:

Online: Visit OilWellCBD.com to order sublingual oil or vape cartridges.

Phone: Call (832) 416-2816—our team will answer questions about shipping to South Dakota, product selection, and usage guidance.

Email: [email protected]

Shipping: We process orders within 24 hours and ship via USPS Priority Mail (2-3 days) or FedEx/UPS Ground (3-5 days) to all South Dakota addresses.

Instagram: @oilwellcbd for updates, educational content, and community stories.

Final Thoughts for South Dakota

South Dakota’s motto is “Under God the People Rule.” That spirit of self-determination aligns perfectly with our patient-controlled potency philosophy. You rule your healthcare decisions—not us, not the government, not the pharmaceutical industry.

We at OilWell Cannabis believe South Dakotans deserve the same access to evidence-based cannabinoid medicine as residents of any other state. Whether you’re a veteran in Rapid City dealing with PTSD, a cancer patient in Sioux Falls seeking nausea relief, a farmer outside Pierre managing chronic pain, or a senior in Aberdeen struggling with sleep—you deserve honest information, quality products, and the freedom to choose.

Our commitment is simple: provide the best possible version of RSO, publish the complete formula so you can make your own if needed, and never sell snake oil. That’s the promise we made in our first ABC13 interview in 2019, and it’s the promise we keep for every South Dakota resident who chooses OilWell.

The choice is yours. The control is yours. The healing is yours.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult your healthcare provider before use. You must be 21 years or older to purchase. Keep out of reach of children. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. South Dakota customers are responsible for verifying local laws and accepting all legal responsibility for purchase, possession, and use.